GlassScriptPhysician profile
Erica Rosa
NPI 1619574795
$3,078.85
in general payments reported to CMS, 2019-2025
24 companies · $1,739 in 2025
The $1,739 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,340 · 2025: $1,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,874 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,873.92 |
| Education | $204.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $533.97 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $461.28 | 2024-2025 | Fasenra, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $313.18 | 2024-2025 | Glassia, Fruzaqla |
| Actelion Pharmaceuticals US, INC. | $265.78 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.78 | 2024-2025 | Ofev, Jascayd, Stiolto Respimat |
| Grifols USA, LLC | $249.16 | 2024-2025 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $111.82 | 2024 | Purified Cortrophin Gel |
| United Therapeutics Corporation | $102.62 | 2025 | Tyvaso |
| Harmony Biosciences LLC | $92.86 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $92.03 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $92.00 | 2024-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $84.30 | 2024-2025 | Acthar |
| Vifor Pharma, INC. | $74.14 | 2024-2025 | Zemaira |
| Lilly USA, LLC | $57.81 | 2025 | Zepbound |
| Verona Pharma, INC. | $50.02 | 2025 | Ohtuvayre |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $49.33 | 2024-2025 | |
| Mylan Specialty L.P. | $42.06 | 2024 | Yupelri |
| Genzyme Corporation | $31.98 | 2025 | |
| Novartis Pharmaceuticals Corporation | $23.40 | 2025 | |
| Caris Mpi, INC. | $23.22 | 2025 | Mi Cancer Seek |
| Baxter Healthcare | $21.26 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Boston Scientific Corporation | $20.33 | 2024 | Bodyguardian |
| Amgen INC. | $18.44 | 2024 | Tezspire |
| Inspire Medical Systems, INC. | $17.08 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Rosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.